Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 2.0% in August: Crecon
October 10, 2018
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- 3 Japan Major Pharmas to Launch 2nd Open Drug Reposition Program
October 10, 2018
- Funding Disclosures Reveal Changes in Money Flows; Biz Models, Pricing Reform Driving the Shift
October 9, 2018
- Osaka Univ. Spinout FunPep Raises 460 Million Yen
October 9, 2018
- Canada Approves Mitsubishi Tanabe’s ALS Med Radicava
October 9, 2018
- Belviq Reduces Risk of Progression to Type 2 Diabetes: Eisai
October 9, 2018
- Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
- Reldesemtiv Shows Efficacy for Spinal Muscular Atrophy in PII: Astellas/Cytokinetics
October 9, 2018
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- Fujifilm Develops New Technology to Search and Design Candidate Compounds Using Structural Formulas Alone
October 5, 2018
- Novo’s Oral GLP-1 Analogue Semaglutide Comparable to Subcutaneous Dulaglutide in No. of AEs: Japan PIIIa Study
October 5, 2018
- Blincyto OK Now in Hand, Amgen Astellas JV Revs Up for Foray into Japan Oncology Market
October 4, 2018
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
- Daiichi Sankyo/Kite’s CAR-T Cell Therapy Scoops Up Orphan Status for B-Cell Lymphoma
October 4, 2018
- Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
October 3, 2018
- Fujifilm, Taisho Detail Sales Schemes after Tie-Up Dissolution Next March
October 3, 2018
- Kaken Grants Distribution Rights for Efinaconazole to Main Life in Hong Kong, Macau
October 3, 2018
- Adcetris Improves PFS as Frontline Therapy for PTCL in PIII: Takeda/Seattle Genetics
October 3, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…